MetaCap

CryoPort (CYRX) vs Nektar Therapeutics (NKTR)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

CryoPort (CYRX) has outperformed Nektar Therapeutics (NKTR) over the past year, gaining 117.0% versus a loss of 44.4%. Over five years, CYRX leads with a -71.4% price change compared with -82.0% for NKTR. Nektar Therapeutics is the larger company by market cap ($1.03 billion vs $964.9 million), about 1.1 times the size, while CryoPort is growing revenue faster (+12.4% vs -43.9%).

CryoPort converts more of its revenue into profit, with a net margin of 44.4% versus -297.1%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CYRX+116.97%NKTR-44.36%
+145%+46%-53%
Nov 21, 20251 yearNov 20, 2026
CYRX-73.63%NKTR-82.94%
+39%-32%-103%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CYRX versus NKTR key metrics
MetricCYRXNKTR
Share price$19.05$30.20
Market cap$964.87M$1.03B
1-day change-2.56%-7.19%
YTD return+98.44%-28.57%
1-year return+116.97%-44.36%
5-year return-71.38%-82.04%
EPS (TTM)$-0.90$-22.47
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$176.18M$55.23M
Revenue growth (YoY)+12.38%-43.89%
Net income (latest FY)$78.30M$-164.08M
Gross margin47.14%100.00%
Operating margin-20.89%-253.66%
Net margin44.44%-297.07%
52-week high$21.78$109.00
52-week low$7.61$30.13
Distance from 52-week high-12.53%-72.29%
Analyst consensusstrong_buybuy
Avg. price target upside+17.22%+336.82%
Average volume843.80K1.12M
Shares outstanding50.65M34.21M
Employees68463
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • CYRX has outperformed NKTR by 161.3 percentage points over the past year.
  • CryoPort is more profitable, keeping 44.4 cents of every revenue dollar as net income versus -297.1 cents for Nektar Therapeutics.
  • CryoPort grew revenue faster in its latest fiscal year (+12.38% vs -43.89%).

About CryoPort

CYRX stock →

Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and reproductive medicine markets worldwide.

Health Care · Biotechnology: Pharmaceutical Preparations · 684 employees

About Nektar Therapeutics

NKTR stock →

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. It develops rezpegaldesleukin, which is in Phase 2b to treat underlying immune system imbalance in people with autoimmune disorders and inflammatory diseases; NKTR-0165 to treat ulcerative colitis, vitiligo, and multiple sclerosis; NKTR-0166 to treat autoimmune disease; NKTR-422 to treat fibrotic diseases; and NKTR-255 to treat solid tumors and large b-cell lymphoma.

Health Care · Biotechnology: Pharmaceutical Preparations · 63 employees

CYRX vs NKTR FAQ

Which is bigger, CryoPort or Nektar Therapeutics?

Nektar Therapeutics (NKTR) is larger, with a market capitalization of $1.03B compared with $964.87M for CryoPort (CYRX).

Which stock has performed better over the past year, CYRX or NKTR?

CYRX returned +116.97% over the past 12 months, compared with -44.36% for NKTR (price return, excluding dividends). Past performance does not predict future results.

Are CryoPort and Nektar Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons